Julie M Strizki

Summary

Affiliation: Schering-Plough Research Institute
Country: USA

Publications

  1. pmc Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1
    Julie M Strizki
    Department of Antiviral Therapy, Schering Plough Research Institute, 2015 Galloping Hill Road, K15, E405C 4945, Kenilworth, New Jersey 07033, USA
    Antimicrob Agents Chemother 49:4911-9. 2005
  2. ncbi request reprint Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly sele
    Jayaram R Tagat
    Schering Plough Research Institute, K 15 2B 2800, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA
    J Med Chem 47:2405-8. 2004
  3. ncbi request reprint Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides
    Stuart W McCombie
    Schering Plough Research Institute, 2015 Galloping Hill Road, K 15 2B 2800, Kenilworth, NJ 07033, USA
    Bioorg Med Chem Lett 13:567-71. 2003
  4. doi request reprint Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc
    Paul McNicholas
    Merck Research Laboratories, Kenilworth, NJ, USA
    J Clin Virol 55:134-9. 2012
  5. doi request reprint Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1)
    Paul M McNicholas
    Department of Infectious Diseases, Merck Research Labs, Kenilworth, NJ 07033, USA
    J Acquir Immune Defic Syndr 56:222-9. 2011
  6. doi request reprint Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial
    Paul McNicholas
    Merck Research Laboratories, Kenilworth, New Jersey 07033, USA
    J Infect Dis 201:1470-80. 2010
  7. doi request reprint Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor
    Peter J Buontempo
    Schering Plough Research Institute, Department of Biological Sciences VIROLOGY, K 15 4950, Kenilworth, Building K 15 4, Mailstop 4950, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Virology 395:268-79. 2009
  8. ncbi request reprint Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity
    Anandan Palani
    Chemical Research, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    J Med Chem 45:3143-60. 2002
  9. pmc Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor
    Shawn E Kuhmann
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Virol 78:2790-807. 2004
  10. ncbi request reprint Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types
    Thomas J Ketas
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA
    AIDS Res Hum Retroviruses 19:177-86. 2003

Collaborators

Detail Information

Publications11

  1. pmc Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1
    Julie M Strizki
    Department of Antiviral Therapy, Schering Plough Research Institute, 2015 Galloping Hill Road, K15, E405C 4945, Kenilworth, New Jersey 07033, USA
    Antimicrob Agents Chemother 49:4911-9. 2005
    ..Vicriviroc represents a promising new candidate for the treatment of HIV-1 infection...
  2. ncbi request reprint Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly sele
    Jayaram R Tagat
    Schering Plough Research Institute, K 15 2B 2800, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA
    J Med Chem 47:2405-8. 2004
    ..Compound 30 (Sch-417690/Sch-D), a potent inhibitor of HIV-1 entry into target cells, is currently in clinical trials...
  3. ncbi request reprint Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides
    Stuart W McCombie
    Schering Plough Research Institute, 2015 Galloping Hill Road, K 15 2B 2800, Kenilworth, NJ 07033, USA
    Bioorg Med Chem Lett 13:567-71. 2003
    ..Compound 16 from the latter set reduced the number of rotamers, improved potency of inhibiting UIV entry, slightly diminished the affinity for the muscarine receptors and showed very good oral absorption...
  4. doi request reprint Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc
    Paul McNicholas
    Merck Research Laboratories, Kenilworth, NJ, USA
    J Clin Virol 55:134-9. 2012
    ..Vicriviroc (VCV), a small-molecule antagonist of the C-C chemokine receptor 5 (CCR5), blocks HIV's entry into CD4+ cells. Small studies have suggested that resistance to CCR5 antagonists is slow to develop...
  5. doi request reprint Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1)
    Paul M McNicholas
    Department of Infectious Diseases, Merck Research Labs, Kenilworth, NJ 07033, USA
    J Acquir Immune Defic Syndr 56:222-9. 2011
    ..Among the 79 VCV-treated subjects, 15 experienced virologic failure, and of these 5 had VCV-resistant virus. This study investigated the molecular basis for the changes in susceptibility to VCV in these subjects...
  6. doi request reprint Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial
    Paul McNicholas
    Merck Research Laboratories, Kenilworth, New Jersey 07033, USA
    J Infect Dis 201:1470-80. 2010
    ..This study explored the molecular basis for the development of phenotypically resistant virus...
  7. doi request reprint Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor
    Peter J Buontempo
    Schering Plough Research Institute, Department of Biological Sciences VIROLOGY, K 15 4950, Kenilworth, Building K 15 4, Mailstop 4950, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Virology 395:268-79. 2009
    ....
  8. ncbi request reprint Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity
    Anandan Palani
    Chemical Research, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    J Med Chem 45:3143-60. 2002
    ....
  9. pmc Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor
    Shawn E Kuhmann
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Virol 78:2790-807. 2004
    ..2-CCR5 cells under conditions where gp120 proteins from the parental virus and a partially AD101-resistant virus bound strongly. Hence, the full impact of the V3 substitutions may only be apparent at the level of the native Env complex...
  10. ncbi request reprint Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types
    Thomas J Ketas
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA
    AIDS Res Hum Retroviruses 19:177-86. 2003
    ....
  11. pmc HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
    Alexandra Trkola
    Division of Infectious Diseases, Department of Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 99:395-400. 2002
    ..Instead, HIV-1 acquires the ability to use CCR5 despite the inhibitor, first by requiring lower levels of CCR5 for entry and then probably by using the drug-bound form of the receptor...